These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16443047)

  • 1. Targeting VEGF in cancer therapy.
    Donovan EA; Kummar S
    Curr Probl Cancer; 2006; 30(1):7-32. PubMed ID: 16443047
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
    Tonra JR; Hicklin DJ
    Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
    Verheul HM; Hammers H; van Erp K; Wei Y; Sanni T; Salumbides B; Qian DZ; Yancopoulos GD; Pili R
    Clin Cancer Res; 2007 Jul; 13(14):4201-8. PubMed ID: 17634549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deal watch: Aveo and Astellas to develop VEGF inhibitor for renal cell carcinoma.
    Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455225
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
    Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
    Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASCO 2007: plenary top 5.
    Oncology (Williston Park); 2007 Jun; 21(7):896. PubMed ID: 17722746
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronotherapy for human solid tumors other than colorectal.
    Focan C
    In Vivo; 1995; 9(6):549-54. PubMed ID: 8726800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal antisense oligonucleotides for cancer therapy.
    Siwak DR; Tari AM; Lopez-Berestein G
    Methods Enzymol; 2004; 387():241-53. PubMed ID: 15172168
    [No Abstract]   [Full Text] [Related]  

  • 10. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conclusion and future directions.
    Samlowski WE; Vogelzang NJ
    Cancer J; 2008; 14(5):330-2. PubMed ID: 18836339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR/VEGF signalling pathway in colorectal cancer: the way we are!
    Spano JP; Milano G; Baselga J
    Bull Cancer; 2005 Aug; 92(Spec no):S3-4. PubMed ID: 16387661
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma.
    Yockman JW; Kim WJ; Chang CW; Kim SW
    Gene Ther; 2007 Oct; 14(19):1399-405. PubMed ID: 17653245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells.
    Dallas NA; Fan F; Gray MJ; Van Buren G; Lim SJ; Xia L; Ellis LM
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):433-41. PubMed ID: 17786539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of vascular endothelial growth factor in kidney and prostate cancer.
    Delongchamps NB; Peyromaure M
    Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
    Simiantonaki N; Jayasinghe C; Michel-Schmidt R; Peters K; Hermanns MI; Kirkpatrick CJ
    Int J Oncol; 2008 Mar; 32(3):585-92. PubMed ID: 18292935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
    Levine AM; Tulpule A; Quinn DI; Gorospe G; Smith DL; Hornor L; Boswell WD; Espina BM; Groshen SG; Masood R; Gill PS
    J Clin Oncol; 2006 Apr; 24(11):1712-9. PubMed ID: 16520466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angiogenesis and lung cancer].
    Pérol M; Arpin D
    Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferons in oncology.
    Woll PJ; Pettengell R
    Br J Clin Pract; 1997 Mar; 51(2):111-5. PubMed ID: 9158255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.